Sideris Giorgos, Katsis Leonidas, Karle Styliani, Korres George
2nd Otolaryngology Department, Attikon University Hospital, National and Kapodistrian University of Athens, 124 62 Athens, Greece.
Audiol Res. 2025 Aug 6;15(4):98. doi: 10.3390/audiolres15040098.
Lermoyez syndrome (LS) is a rare variant of endolymphatic hydrops with a unique clinical presentation characterized by reversible sensorineural hearing loss preceding vertigo. This review aims to synthesize available literature on LS to clarify its clinical characteristics, diagnostic approach, management strategies, and outcomes, and to highlight the distinguishing features from Menière's disease (MD). A systematic literature review according to PRISMA guidelines was conducted from 1919 to 2025. The extracted data included demographics, symptom profiles, audiovestibular testing, imaging findings, treatment approaches, and patient outcomes. A total of 23 studies were identified, reporting 53 individual cases of LS. Patients ranged from 27 to 85 years of age, with a mean age of 50.34 years and a male predominance (64.1%). The hallmark of LS across cases was a reproducible clinical pattern of unilateral low-frequency hearing loss followed by vertigo and subsequent auditory recovery. Audiometry typically confirmed reversible sensorineural hearing loss, while vestibular tests and imaging were often unremarkable, primarily used to exclude alternative diagnoses. Treatment approaches varied and were often based on MD protocols, including dietary modifications, vasodilators, diuretics, and vestibular suppressants. Prognosis was generally favorable, with most patients experiencing both hearing recovery and symptom resolution. LS remains a clinically distinct but underrecognized inner ear disorder. Its defining feature-the paradoxical improvement in hearing after vertigo-distinguishes it from Menière's disease and should prompt clinicians to consider LS in differential diagnosis. Due to the rarity of LS and the lack of standardized guidelines, diagnosis and treatment rely on careful clinical assessment and individualized management strategies.
勒莫耶兹综合征(LS)是一种罕见的内淋巴积水变异型,具有独特的临床表现,其特征为眩晕前出现可逆性感音神经性听力损失。本综述旨在综合有关LS的现有文献,以阐明其临床特征、诊断方法、管理策略和预后,并突出与梅尼埃病(MD)的区别特征。根据PRISMA指南,对1919年至2025年的文献进行了系统综述。提取的数据包括人口统计学、症状特征、听前庭测试、影像学检查结果、治疗方法和患者预后。共纳入23项研究,报告了53例LS个体病例。患者年龄在27岁至85岁之间,平均年龄为50.34岁,男性占主导(64.1%)。各病例中LS的标志是一种可重复的临床模式,即单侧低频听力损失,随后出现眩晕,随后听力恢复。听力测定通常证实为可逆性感音神经性听力损失,而前庭测试和影像学检查通常无明显异常,主要用于排除其他诊断。治疗方法各不相同,通常基于MD方案,包括饮食调整、血管扩张剂、利尿剂和前庭抑制剂。预后一般良好,大多数患者听力恢复且症状缓解。LS仍然是一种临床上独特但未得到充分认识的内耳疾病。其定义特征——眩晕后听力出现矛盾性改善——使其有别于梅尼埃病,应促使临床医生在鉴别诊断时考虑LS。由于LS罕见且缺乏标准化指南,诊断和治疗依赖于仔细的临床评估和个体化管理策略。